Immunome, Inc. (IMNM) is a publicly traded Healthcare sector company. As of May 20, 2026, IMNM trades at $21.47 with a market cap of $2.25B and a P/E ratio of -8.89. IMNM moved +9.59% today. Year to date, IMNM is +9.23%; over the trailing twelve months it is +151.52%. Its 52-week range spans $5.15 to $27.65. Analyst consensus is strong buy with an average price target of $35.17. Rallies surfaces IMNM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who is trading IMNM stock inside the company?
Recent IMNM insider activity includes BIENAIME JEAN JACQUES bought 5.00K, Higgins Jack sold 9.44K, Rosett Max sold 63.66K, Rosett Max sold 1.34K, and SIEGALL CLAY B bought 25.45K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
IMNM Key Metrics
Key financial metrics for IMNM
Metric
Value
Price
$21.47
Market Cap
$2.25B
P/E Ratio
-8.89
EPS
$-2.38
Dividend Yield
0.00%
52-Week High
$27.65
52-Week Low
$5.15
Volume
1.14M
Avg Volume
0
Revenue (TTM)
$4.01M
Net Income
$-224.59M
Gross Margin
0.00%
Recent IMNM Insider Trades
BIENAIME JEAN JACQUES bought 5.00K (~$103.50K) on May 15, 2026.
Higgins Jack sold 9.44K (~$204.24K) on Apr 2, 2026.
Rosett Max sold 63.66K (~$1.39M) on Apr 2, 2026.
Rosett Max sold 1.34K (~$30.21K) on Apr 2, 2026.
SIEGALL CLAY B bought 25.45K (~$500.60K) on Mar 27, 2026.
Recent IMNM insider activity includes BIENAIME JEAN JACQUES bought 5.00K, Higgins Jack sold 9.44K, Rosett Max sold 63.66K, Rosett Max sold 1.34K, and SIEGALL CLAY B bought 25.45K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for IMNM?
Yes. Rallies tracks IMNM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is IMNM research on Rallies investment advice?
No. Rallies provides research, data, and educational context for IMNM. It does not provide personalized investment advice.
